About compugen - CGEN
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
CGEN At a Glance
Compugen Ltd.
Azrieli Center
Holon, Tel Aviv 58858
| Phone | 972-3-765-8585 | Revenue | 27.86M | |
| Industry | Biotechnology | Net Income | -14,231,000.00 | |
| Sector | Health Technology | Employees | 74 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
CGEN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.916 |
| Price to Book Ratio | 2.495 |
| Price to Cash Flow Ratio | 2.76 |
| Enterprise Value to EBITDA | -2.543 |
| Enterprise Value to Sales | 1.315 |
| Total Debt to Enterprise Value | 0.079 |
CGEN Efficiency
| Revenue/Employee | 376,540.541 |
| Income Per Employee | -192,310.811 |
| Receivables Turnover | 103.584 |
| Total Asset Turnover | 0.236 |
CGEN Liquidity
| Current Ratio | 5.258 |
| Quick Ratio | 5.258 |
| Cash Ratio | 5.122 |
CGEN Profitability
| Gross Margin | 71.54 |
| Operating Margin | -53.442 |
| Pretax Margin | -34.844 |
| Net Margin | -51.073 |
| Return on Assets | -12.043 |
| Return on Equity | -23.625 |
| Return on Total Capital | -24.61 |
| Return on Invested Capital | -23.017 |
CGEN Capital Structure
| Total Debt to Total Equity | 5.303 |
| Total Debt to Total Capital | 5.036 |
| Total Debt to Total Assets | 2.532 |
| Long-Term Debt to Equity | 4.487 |
| Long-Term Debt to Total Capital | 4.261 |